Howard L Kaufman

List of Publications by Year
in descending order

159 papers	14,611 citations	57758 44 h-index	24258 110 g-index
164 all docs	164 docs citations	164 times ranked	13247 citing authors

#	Article	IF	Citations
1	Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study. Journal of the American Academy of Dermatology, 2022, 87, 434-435.	1.2	3
2	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrology Dialysis Transplantation, 2022, 37, 507-514.	0.7	10
3	Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. Clinical Cancer Research, 2022, 28, 2211-2220.	7.0	23
4	Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Frontiers in Molecular Biosciences, 2022, 9, 834841.	3.5	23
5	Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on â€œFighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignanciesâ€. Annals of Surgical Oncology, 2021, 28, 2432-2433.	1.5	0
6	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine, 2021, 69, 888-892.	1.6	10
7	Advancing oncolytic virus therapy by understanding the biology. Nature Reviews Clinical Oncology, 2021, 18, 197-198.	27.6	19
8	Can Biomarkers Guide Oncolytic Virus Immunotherapy?. Clinical Cancer Research, 2021, 27, 3278-3279.	7.0	11
9	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. Cancer Research, 2021, 81, CT139-CT139.	0.9	8
10	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. Journal of Clinical Oncology, 2021, 39, 3829-3838.	1.6	44
11	Immunotherapy for Non-melanoma Skin Cancer. Current Oncology Reports, 2021, 23, 125.	4.0	49
12	Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2021, 85, 1038-1040.	1.2	15
13	Synthetic biology: at the crossroads of genetic engineering and human therapeuticsâ€”a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, , .	3.8	2
14	Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma. Laryngoscope, 2021, , .	2.0	11
15	Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. Methods in Enzymology, 2020, 635, 167-184.	1.0	4
16	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1119-1128.	7.1	140
17	Clinical landscape of oncolytic virus research in 2020. , 2020, 8, e001486.		191
18	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15

#	Article	IF	Citations
19	An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. American Journal of Clinical Dermatology, 2020, 21, 821-832.	6.7	24
20	Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. , 2020, 8, e000112.		3
21	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
22	422â€…An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. , 2020, , .		5
23	421â€…Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. , 2020, , .		3
24	Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. , 2019, 7, 214.		86
25	Oncolytic Immunotherapy. Surgical Oncology Clinics of North America, 2019, 28, 419-430.	1.5	8
26	Two roads for oncolytic immunotherapy development. , 2019, 7, 26.		28
27	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage IIIâ€“IV melanoma. , 2019, 7, 145.		261
28	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
29	Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. OncoImmunology, 2019, 8, e1591875.	4.6	78
30	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
31	Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. , 2019, 23, E1-E9.		3
32	Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. OncoImmunology, 2019, 8, e1571390.	4.6	1
33	Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. Journal of Biological Methods, 2019, 6, e112.	0.6	8
34	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology, 2019, 9, 1483.	2.8	10
35	Management of Metastatic Melanoma in 2018. JAMA Oncology, 2018, 4, 857.	7.1	26
36	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncology, 2018, 14, 255-266.	2.4	22

#	Article	IF	Citations
37	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
38	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. JAMA Oncology, 2018, 4, e180077.	7.1	304
39	Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. Journal of Cutaneous Pathology, 2018, 45, 48-53.	1.3	19
40	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	1.6	483
41	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science Translational Medicine, 2018, 10, .	12.4	97
42	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
43	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
44	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock		12
45	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after â‰¥1Âyear of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
46	Integrating oncolytic viruses in combination cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 498-513.	22.7	448
47	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2245-2261.	2.5	28
48	Unleashing the therapeutic potential of oncolytic viruses. Journal of Clinical Investigation, 2018, 128, 1258-1260.	8.2	22
49	Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.. Journal of Clinical Oncology, 2018, 36, 4578-4578.	1.6	1
50	Rational Combination Immunotherapy: Understand the Biology. Cancer Immunology Research, 2017, 5, 355-356.	3.4	5
51	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. American Journal of Clinical Dermatology, 2017, 18, 1-15.	6.7	215
52	Finding gold in tumour immunotherapy. Lancet Oncology, The, 2017, 18, e561.	10.7	0
53	Avelumab and other recent advances in Merkel cell carcinoma. Future Oncology, 2017, 13, 2771-2783.	2.4	11
54	High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opinion on Drug Safety, 2017, 16, 1347-1357.	2.4	60

#	Article	IF	Citations
55	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology, 2017, 6, e1338237.	4.6	47
56	Intratumoral Approaches for the Treatment of Melanoma. Cancer Journal (Sudbury, Mass), 2017, 23, 40-47.	2.0	45
57	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
58	Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunology, Immunotherapy, 2017, 66, 9-16.	4.2	9
59	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37
60	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy, 2016, Volume 9, 7081-7093.	2.0	83
61	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
62	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	10.7	1,034
63	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	4.2	89
64	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyteâ€macrophage colonyâ€stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head and Neck, 2016, 38, 1752-1758.	2.0	49
65	IFN-Î» cancer immunotherapy: new kid on the block. Immunotherapy, 2016, 8, 877-888.	2.0	30
66	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Reports, 2016, 17, 957-965.	6.4	22
67	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology, 2016, 34, 2619-2626.	1.6	449
68	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Annals of Surgical Oncology, 2016, 23, 4169-4177.	1.5	236
69	Surgical Management of Melanoma. Cancer Treatment and Research, 2016, 167, 149-179.	0.5	14
70	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical Cancer Research, 2016, 22, 1048-1054.	7.0	226
71	Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, 9553-9553.	1.6	2
72	A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21006-e21006.	1.6	2

#	Article	IF	Citations
73	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.	1.6	1
74	Interleukin-12. , 2016, , 1-15.		0
75	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
76	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	1.6	1,988
77	Combination Immunotherapy for Melanoma. JAMA Oncology, 2015, 1, 387.	7.1	3
78	Introduction on Cancer Immunology and Immunotherapy. , 2015, , 1-8.		2
79	Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 2015, 14, 642-662.	46.4	1,055
80	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1â€“derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 2015, 15, 1389-1403.	2.4	102
81	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.. Journal of Clinical Oncology, 2015, 33, 9019-9019.	1.6	11
82	Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 9030-9030.	1.6	44
83	High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2015, 33, 423-423.	1.6	3
84	A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS3095-TPS3095.	1.6	0
85	Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress. Neoplasia, 2014, 16, 824-834.	5.3	32
86	Modified Oncolytic Herpesviruses for Gene Therapy of Cancer. , 2014, , 213-223.		0
87	Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virotherapy, 2014, 3, 11.	6.0	19
88	Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules. Human Gene Therapy, 2014, 25, 452-460.	2.7	14
89	Melanoma as a model for precision medicine in oncology. Lancet Oncology, The, 2014, 15, 251-253.	10.7	6
90	CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.. Journal of Clinical Oncology, 2014, 32, 3031-3031.	1.6	17

#	Article	IF	Citations
91	High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2014, 32, 4523-4523.	1.6	4
92	Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. Journal of Clinical Oncology, 2014, 32, 9029-9029.	1.6	43
93	Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. Journal of Clinical Oncology, 2014, 32, 9054-9054.	1.6	3
94	High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. Journal of Clinical Oncology, 2014, 32, 430-430.	1.6	2
95	The Use of Oncolytic Herpesvirus for the Treatment of Cancer. , 2014, , 329-345.		0
96	Cytokines in the Treatment of Cancer. , 2013, , 173-210.		1
97	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. American Journal of Clinical Dermatology, 2013, 14, 179-194.	6.7	89
98	Oncolytic virus therapy for cancer. Oncolytic Virotherapy, 2013, 2, 31.	6.0	42
99	Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.. Journal of Clinical Oncology, 2013, 31, 9050-9050.	1.6	3
100	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	21
101	CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.. Journal of Clinical Oncology, 2013, 31, TPS3128-TPS3128.	1.6	7
102	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	67
103	Interleukin 2. , 2013, , 1-12.		0
104	CTLA-4. , 2013, , 1-14.		0
105	An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, TPS3114-TPS3114.	1.6	0
106	TroVax^{Â®}vaccine therapy for renal cell carcinoma. Immunotherapy, 2012, 4, 27-42.	2.0	14
107	Vaccines for Melanoma and Renal Cell Carcinoma. Seminars in Oncology, 2012, 39, 263-275.	2.2	29
108	OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8604-TPS8604.	1.6	2

#	Article	IF	Citations
109	Modulating the Tumor Microenvironment. , 2012, , 353-369.		0
110	Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 2588-2588.	1.6	0
111	gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. New England Journal of Medicine, 2011, 364, 2119-2127.	27.0	809
112	An update on TroVax® for the treatment of progressive castration-resistant prostate cancer. OncoTargets and Therapy, 2011, 4, 33.	2.0	2
113	MVAâ€“5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunology, Immunotherapy, 2011, 60, 829-837.	4.2	34
114	Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma. Annals of Surgical Oncology, 2010, 17, 718-730.	1.5	451
115	Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Clinical Cancer Research, 2010, 16, 5539-5547.	7.0	184
116	TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. Hum Vaccin, 2010, 6, 784-791.	2.4	31
117	OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncology, 2010, 6, 941-949.	2.4	195
118	Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factorâ€“Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. Journal of Clinical Oncology, 2009, 27, 5763-5771.	1.6	540
119	Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. Journal of Clinical Oncology, 2009, 27, 2645-2652.	1.6	167
120	Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Journal of Translational Medicine, 2009, 7, 2.	4.4	64
121	Gene Therapy for Antitumor Vaccination. Methods in Molecular Biology, 2009, 542, 515-527.	0.9	4
122	Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 685-691.	4.2	83
123	Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2008, 14, 4843-4849.	7.0	105
124	Cytokine Therapy for Cancer. Surgical Oncology Clinics of North America, 2007, 16, 793-818.	1.5	26
125	Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. Journal of Translational Medicine, 2007, 5, 60.	4.4	102
126	TNFâ€Î±â€induced activation of RhoA/Rho kinase pathway in human pulmonary microvascular endothelial cells. FASEB Journal, 2007, 21, A1201.	0.5	2

#	Article	IF	Citations
127	High Dose Interleukin-2 Therapy. , 2007, , 431-452.		0
128	Combination Cytokine Therapy. , 2007, , 373-398.		0
129	Viral Vaccines for Cancer Immunotherapy. Hematology/Oncology Clinics of North America, 2006, 20, 661-687.	2.2	11
130	The tumour microenvironment and implications for cancer immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 671-684.	3.1	39
131	Characterization of CD4⁺CD25⁺ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 1169-1177.	1.6	330
132	Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors. Human Gene Therapy, 2006, 17, 239-244.	2.7	73
133	DNA Vaccines for Cancer Immunotherapy. , 2006, , 87-114.		0
134	Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules. Annals of the New York Academy of Sciences, 2005, 1062, 41-50.	3.8	6
135	Pox Viral Vaccine Approaches. Seminars in Oncology, 2005, 32, 549-555.	2.2	41
136	Columbia University. Lancet Oncology, The, 2005, 6, 750.	10.7	0
137	Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. Lancet Oncology, The, 2005, 6, 62-63.	10.7	5
138	Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. Journal of Clinical Investigation, 2005, 115, 1903-1912.	8.2	126
139	Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 2122-2132.	1.6	226
140	The lymphoid chemokine CCL21 costimulates naÃ¯ve T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cellular Immunology, 2004, 231, 75-84.	3.0	113
141	Immunotherapy for melanoma. Clinics in Dermatology, 2004, 22, 251-265.	1.6	50
142	Surgical treatment of stage IV melanoma. Clinics in Dermatology, 2004, 22, 240-250.	1.6	15
143	Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine, 2004, 22, 2894-2903.	3.8	24
144	Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. Journal of Clinical Investigation, 2004, 113, 664-667.	8.2	47

#	Article	IF	Citations
145	DNA Vaccines. , 2004, , 225-248.		0
146	The role of poxviruses in tumor immunotherapy. Surgery, 2003, 134, 731-737.	1.9	10
147	Prostate-specific antigen vaccines for prostate cancer. Expert Opinion on Biological Therapy, 2002, 2, 395-408.	3.1	17
148	Chemokines and Cancer. Cancer Investigation, 2002, 20, 825-834.	1.3	6
149	COMBINATION INTERLEUKIN-2 AND INTERLEUKIN-12 INDUCES SEVERE GASTROINTESTINAL TOXICITY AND EPITHELIAL CELL APOPTOSIS IN MICE. Cytokine, 2002, 17, 43-52.	3.2	10
150	Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine, 2002, 20, 1862-1869.	3.8	45
151	Immunotherapy for pancreatic cancer: current concepts. Hematology/Oncology Clinics of North America, 2002, 16, 159-197.	2.2	20
152	Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunology, Immunotherapy, 2000, 49, 504-514.	4.2	195
153	Innovations and strategies for the development of anticancer vaccines. Expert Opinion on Pharmacotherapy, 2000, 1, 603-614.	1.8	4
154	Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert Reviews in Molecular Medicine, 2000, 2, 1-24.	3.9	18
155	Current Issues in Cancer Vaccine Development. Clinical Immunology, 1999, 92, 211-223.	3.2	12
156	Small bowel obstruction by jejunal enterolith. Surgery, 1997, 121, 229-230.	1.9	9
157	Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Annals of Surgical Oncology, 1996, 3, 495-500.	1.5	91
158	Leiomyoma of the breast. , 1996, 62, 62-64.		22
159	A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). International Journal of Cancer, 1991, 48, 900-907.	5.1	73